Cerenis gains $53.5M in new venture funds

Cerenis Therapeutics--which has operations in Ann Arbor, MI and Toulouse, France focused on developing a new cholesterol drug--has raised $53.5 million in its second round of venture financing. TVM Capital led the round with additional funds from Orbimed, Sofinnova Partners of France, HealthCap of Sweden, Alta Partners and EDF Ventures of the U.S. and NIF SMBC Ventures of Japan. Cerenis says much of the money will be used to back the development of its lead compound, Cerenis HDL, a synthetic form of HDL (high-density lipoprotein, also known as "good cholesterol") that mimics natural HDL in humans.

- here's the release on the latest round

ALSO: Yaupon Therapeutics has raised $4 million in its second round of financing. Release

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.